Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Over 3,600 bottles of thyroid medication pulled from shelves. Vitruvias Therapeutics has voluntarily recalled a batch of Thyroid Tablets, USP 30 mg after lab tests showed the pills may be too potent. No adverse events have been reported so far, but patients on the affected lot are urged to contact their doctor immediately.
Vitruvias Therapeutics, based in Auburn, Alabama, has issued a voluntary nationwide recall of one lot of Thyroid Tablets, USP 30 mg after laboratory testing revealed the pills may be overpotent. The recall targets lot number 504950 (expiration: Sept. 30, 2026; NDC: 69680-166-00), with nearly 1,955 of the 3,655 released bottles already sold to wholesalers and direct accounts across the U.S. between January and September of last year.
As of late August, no adverse health events or side effects linked to the recalled batch have been reported. Still, the FDA and the company are urging anyone taking the affected tablets to consult their physician right away. Thyroid medication that is too strong can trigger hyperthyroidism, and high-risk groups — including elderly patients, pregnant women, and infants — face the greatest potential harm.
Key Takeaways:
Why it matters: Even without reported harm so far, overpotent thyroid medication poses real risks — especially for vulnerable populations. Clinicians should proactively identify patients on the recalled lot and reassess their thyroid management plans.
